Anal Cancer Market is expected to witness significant growth over the forecast period. The market was valued at approximately USD 673.92 million in 2018 and is projected to register a 6.46% CAGR over the forecast period.

Anal cancer is a rare type of malignancy that starts in the anus, which is the opening at the end of the rectum.

Factors such as the rising prevalence of anal cancer and the growing number of sexually transmitted diseases are expected to drive market growth. According to an article published by the American Cancer Society, an estimated 8,300 new cases of anal cancer will be diagnosed in 2019. Moreover, increasing research and development expenditure in the field of oncology is also expected to boost market growth.

However, the side effects of the treatment and lack of awareness are expected to hamper the market growth.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1530

Segmentation

The global anal cancer market has been segmented into cancer type, treatment type, end user, and region.

Based on cancer type, the global anal cancer market has been segmented into carcinoma in situ, squamous cell carcinoma, melanoma, adenocarcinoma, basal cell carcinoma, and others.

The global anal cancer market, by treatment type, has been segmented into chemotherapy, surgery, radiation therapy, and immunotherapy.

The global anal cancer market, by end user, has been segmented into hospitals & clinics, research & academic institutes, and others.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The anal cancer market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.

The European anal cancer market has been segmented into Western Europe and Eastern Europe. The market in Western Europe has further been classified into France, Germany, Spain, the UK, Italy, and the rest of Western Europe.

The anal cancer market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.

The Middle East & Africa anal cancer market is segmented into the Middle East and Africa.

Key Players

Amgen Inc. (US), Bristol-Myers Squibb Company (US), Celgene Corporation (US), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd (Switzerland), Merck & Co., Inc. (US), Novartis AG (Switzerland), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Sanofi (France), Johnson & Johnson Services, Inc. (US) and Hospira, Inc. (US) are some of the key players operating in the global anal cancer market.

Geographically, the market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to dominate the anal cancer market owing to the rising prevalence of anal cancer. According to the American Cancer Society, by 2019, approximately 1,280 people are expected to die from anal cancer.

Europe is expected to hold the second-largest share of the anal cancer market owing to the rising prevalence of anal cancer and presence of major market players such as F. Hoffmann-La Roche Ltd, Novartis AG, GlaxoSmithKline plc, and Sanofi. According to Cancer Research UK, 1,438 new cases of anal cancer were found in between 2014–2016 in the UK.

Asia-Pacific is expected to be the fastest-growing regional market owing to the increasing awareness regarding cancer and rising prevalence of sexually transmitted diseases.

The anal cancer market in the Middle East & Africa is expected to steadily grow during the forecast period owing to the high incidence rate of anal cancer.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/anal-cancer-market-1530